Wegovy FlexTouch 1.7mg/0.75ml Solution For Injection In Pre-filled Pen

Wegovy FlexTouch 1.7mg/0.75mL is a prescription injectable medicine containing semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist manufactured by Novo Nordisk, supplied in a single-use pre-filled pen. Unlike Ozempic, which contains the same active ingredient but is registered for type 2 diabetes, Wegovy is specifically indicated for chronic weight management in adults with obesity, or who are overweight with at least one weight-related medical condition, when used together with a reduced-calorie diet and increased physical activity.

The 1.7mg/0.75mL FlexTouch pen represents one step in a gradual, doctor-supervised dose-titration schedule that begins at a low dose and increases every four weeks to reduce gastrointestinal side effects. Wegovy is intended for long-term use as part of an overall weight-management programme that includes lifestyle changes, and it should only be started, titrated, or stopped under medical supervision.

Semaglutide mimics the naturally occurring hormone GLP-1, activating GLP-1 receptors in the pancreas, gut, and brain. This increases insulin release when blood glucose is elevated, reduces glucagon secretion, slows the rate at which the stomach empties, and acts on appetite-regulating centres in the brain to reduce hunger and increase feelings of fullness, resulting in reduced food intake and, over time, weight loss.

Wegovy FlexTouch is injected subcutaneously (under the skin) into the abdomen, thigh, or upper arm, with the injection site rotated at each dose. Each pen is pre-set to deliver a single dose and must be disposed of after one use, even if some solution remains visible in the pen window. Patients should be trained on correct injection technique by a healthcare professional before self-administering. If a dose is missed and it has been less than 5 days, take it as soon as possible; if more than 5 days have passed, skip the missed dose and resume the regular weekly schedule – do not take two doses close together.

Wegovy treatment is started at a low dose (0.25mg once weekly) and increased approximately every 4 weeks, following a fixed dose-escalation schedule, up to the maintenance dose of 2.4mg once weekly recommended by the prescribing doctor. The 1.7mg/0.75mL pen represents one step within this schedule and is injected once weekly, on the same day each week, at any time of day, with or without food. The exact titration pace, target maintenance dose, and duration of treatment should always follow the doctor’s individualised plan.

Use this product before the expiry date stated on the packaging. Do not use the medicine if the expiry date has passed.

Store unused Wegovy FlexTouch pens in a refrigerator (2°C to 8°C); do not freeze, and discard the pen if it has been frozen. Once in use, a pen may be kept below 30°C or refrigerated for up to 6 weeks, with the cap on, away from direct light and heat, and out of reach of children.

• Known hypersensitivity to semaglutide or any component of the formulation
• Personal or family history of medullary thyroid carcinoma
• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Not recommended during pregnancy or breastfeeding – Wegovy should be stopped at least 2 months before a planned pregnancy

• May increase the risk of low blood glucose (hypoglycaemia) when used with insulin or sulfonylureas – your doctor may need to adjust these medicines
• Delayed gastric emptying may affect the absorption of oral medicines, including oral contraceptives, taken around the same time
• Alcohol may worsen gastrointestinal side effects such as nausea and should be limited during treatment
• Always inform your doctor of all prescription medicines, over-the-counter products, and supplements you are taking before starting Wegovy

• Inject on the same day each week to build a consistent routine
• Rotate injection sites between the abdomen, thigh, and upper arm
• Eat smaller, slower meals and avoid high-fat foods in the first few weeks to help reduce nausea
• Seek medical attention promptly for severe or persistent abdominal pain, as this can occasionally indicate pancreatitis